IgG1 and IgG4 antibodies against Aedes aegypti salivary proteins and risk for dengue infections.
Jenny C CardenasPapa M DrameKarina A Luque-BurgosJuan D BerrioElsi Entrena-MutisMaría U GonzálezDaisy J CarvajalLady Y Gutiérrez-SilvaLucio D CardenasTonya M ColpittsChristopher N MoresBerlin Londono-RenteríaPublished in: PloS one (2019)
Dengue virus (DENV) is an arbovirus responsible for a significant number of deaths in Latin America. This virus is transmitted through the bite of Aedes aegypti, the main mosquito vector, and Ae. albopictus. During blood uptake, the mosquito injects its saliva into the host to facilitate the feeding process. Mosquito saliva contains potent immunogens capable of inducing antibody production directly related to mosquito bite exposure intensity and disease risk. In this study, we first determined the DENV infection status by two different DENV non-structural protein 1 (NS1) based rapid tests and qRT-PCR, then measured the levels of IgG1 and IgG4 antibodies against salivary proteins of Ae. aegypti female mosquitoes in volunteers living in a dengue endemic area. Our results show that people with a positive DENV diagnosis present higher levels of IgG4 antibodies than people with a negative diagnostic test, and that these antibody levels were higher in people with secondary DENV infections. With this study, we show that detection of IgG4 antibodies against mosquito saliva may be a reliable method to evaluate the risk of dengue infection.